Anti-toxoplasmosis treatment
PreclinicalSmall molecule
Anti-toxoplasmosis treatment is one of 4 small molecule programs targeting Toxoplasmosis. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Toxoplasmosis
#DrugCompanyPhaseTrials
1Daraprim
FFondazione Matilde Tettamanti Menotti De Marchi Onlus
Approved
Trimethoprim-Sulfamethoxazole
AstellasPhase 3
Wellcovorin
EEastern Cooperative Oncology Group
Phase 1
Anti-toxoplasmosis treatment
UUniversity Hospital, Grenoble
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity Hospital, Grenoble